公开(公告)号：US06262256B1

公开(公告)日：2001-07-17

申请号：US09073646

申请日：1998-05-06

申请人： Henrik Elsner ,  Søren Mouritsen

发明人： Henrik Elsner ,  Søren Mouritsen

IPC分类号： C08B3702

CPC分类号： C07K17/08 ,  C07K1/042 ,  C12N11/06 ,  G01N33/545 ,  G01N33/548

摘要： A method of modifying the binding properties on a surface of a solid phase on which there are nucleophilic groups, which is characterized in that the surface is treated with a solution of an activated polysaccharide; a method of immobilizing a chemical compound to a solid phase on which there are immobilized activated polysaccharides, whereby the chemical compound is contacted with the surface of the solid phase the binding properties of which are modified by the method according to the invention; an article which is characterized in that to the surface thereof an activated polysaccharide is fixated, such as activated dextran or activated agarose, and use of this article for use in solid phase reactions, in solid phase assay, solid phase peptide synthesis, solid phase nucleotide synthesis, solid phase enzyme processing, and joining of biological surfaces.

摘要翻译： 一种修饰在其上具有亲核基团的固相表面上的结合性质的方法，其特征在于表面用活化多糖的溶液处理; 将化合物固定在其上固定有活化多糖的固相的方法，由此化学化合物与固相的表面接触，其结合性质通过本发明的方法进行改性; 其特征在于，其活性多糖被固定，例如活化的葡聚糖或活化的琼脂糖，并使用该制品用于固相反应，固相测定，固相肽合成，固相核苷酸 合成，固相酶加工和生物表面的接合。

公开(公告)号：US07118750B1

公开(公告)日：2006-10-10

申请号：US09060294

申请日：1998-04-15

申请人： Martin Roland Jensen ,  Søren Mouritsen ,  Henrik Elsner ,  Iben Dalum

发明人： Martin Roland Jensen ,  Søren Mouritsen ,  Henrik Elsner ,  Iben Dalum

IPC分类号： A61K38/19 ,  C07K14/25

CPC分类号： C07K14/525 ,  A61K38/00 ,  A61K39/00 ,  C07K19/00 ,  C07K2319/00 ,  Y10S930/144

摘要： A modified human TNFα molecule is capable of raising neutralizing antibodies towards unmodified human TNFα following administration of the modified TNFα to a human host, wherein one or more peptide fragments of the human TNFα molecule has been substituted by one or more peptides containing immunodominant T cell epitopes or a truncated form of the molecule containing the immunodominant epitope and one or both flanking regions of the human TNFα-molecule containing at least one TNFα B cell epitope, wherein the substitution introduces a substantial change in the amino acid sequence of any one of the strands of the front β-sheet, in any one of the connecting loops, or in any one of the B′, I, or D strands of the back β-sheet.

摘要翻译： 在将修饰的TNFα施用于人宿主后，经修饰的人TNFα分子能够提供针对未修饰的人TNFα的中和抗体，其中人TNFα分子的一个或多个肽片段已被含有免疫优势T细胞表位的一种或多种肽取代 或包含免疫显性表位和含有至少一种TNFαb细胞表位的人TNFα分子的一个或两个侧翼区域的分子的截短形式，其中所述取代引入任何一条链的氨基酸序列的显着变化 在任何一个连接环中，或在背面β片中的任何一个B'，I或D链中的前β片。

公开(公告)号：US07070784B1

公开(公告)日：2006-07-04

申请号：US10031342

申请日：2000-07-20

申请人： Torben Halkier ,  Søren Mouritsen ,  Steen Klysner

发明人： Torben Halkier ,  Søren Mouritsen ,  Steen Klysner

IPC分类号： A61K39/00 ,  C07K14/00

CPC分类号： C07K14/475 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0005 ,  A61K48/00 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/55522 ,  C07K2319/00

摘要： Disclosed are novel methods for increasing muscle mass by means of immunization against Growth Differentiation Factor 8 (GDF-8, myostatin). Immunization is preferably effected by administration of analogues of GDF-8 which are capable of inducing antibody production against homologous GDF-8. Especially preferred as an immunogen is homologous GDF-8 which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the tertiary structure of the homologous GDF-8. Also disclosed are nucleic acid vaccination against GDF-8 and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for identification of useful immunogenic GDF-8 analogues, methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

摘要翻译： 公开了通过免疫接种生长分化因子8（GDF-8，肌生成抑制素）来增加肌肉质量的新方法。 免疫优选通过施用能够诱导针对同源GDF-8的抗体产生的GDF-8的类似物来实现。 特别优选的是作为免疫原的同源GDF-8，其通过引入一个或多个外来的免疫显性和混杂的T细胞表位而被修饰，同时基本上保留了同源的GDF-8的三级结构。 还公开了针对GDF-8的核酸疫苗接种和使用活疫苗的疫苗接种以及用于疫苗接种的方法和装置。 这些方法和手段包括鉴定有用的免疫原性GDF-8类似物的方法，制备类似物和药物制剂的方法，以及核酸片段，载体，转化细胞，多肽和药物制剂。

公开(公告)号：US07005498B1

公开(公告)日：2006-02-28

申请号：US09806703

申请日：1999-10-05

申请人： Lucilla Steinaa ,  Søren Mouritsen ,  Anand Gautam ,  Iben Dalum ,  Jesper Hanning ,  Dana Leach ,  Klaus Gregorius Nielsen ,  Gunilla Karlsson ,  Peter Birk Rasmussen

发明人： Lucilla Steinaa ,  Søren Mouritsen ,  Anand Gautam ,  Iben Dalum ,  Jesper Hanning ,  Dana Leach ,  Klaus Gregorius Nielsen ,  Gunilla Karlsson ,  Peter Birk Rasmussen

IPC分类号： C07K9/00

CPC分类号： C07K16/3069 ,  A61K39/0011 ,  C07K14/50 ,  C07K14/705 ,  C07K14/70539 ,  C07K14/71 ,  C07K2317/34 ,  C12N2799/021 ,  Y02A50/412

摘要： A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.

摘要翻译： 公开了一种用于诱导针对细胞抗原的细胞介导的免疫的方法。 更具体地，本发明提供了一种诱导针对弱抗原，特别是自身蛋白的细胞毒性T淋巴细胞免疫的方法。 该方法需要抗原呈递细胞被诱导以呈现弱抗原的至少一个CTL表位，并且同时呈现至少一种外来T辅助淋巴细胞表位。 在优选的实施方案中，抗原是癌特异性抗原，例如 PSM，Her2或FGF8b。 该方法可以通过使用传统的多肽疫苗接种，也可以通过使用活减毒疫苗或核酸接种来进行。 本发明还提供了PSM，Her2和FGF8b的免疫原性类似物以及编码这些类似物的核酸分子。 还公开了载体和转化的细胞。 本发明还提供了用于鉴定弱或非免疫原性抗原的免疫原性类似物的方法。

公开(公告)号：US07820633B2

公开(公告)日：2010-10-26

申请号：US10441779

申请日：2003-05-19

申请人： Lucilla Steinaa ,  Jesper Haaning ,  Iben Dalum ,  Peter Birk ,  Dana Leach ,  Klaus Gregorius Nielsen ,  Gunilla Karlsson ,  Anand Gautam ,  Søren Mouritsen

发明人： Lucilla Steinaa ,  Jesper Haaning ,  Iben Dalum ,  Peter Birk ,  Dana Leach ,  Klaus Gregorius Nielsen ,  Gunilla Karlsson ,  Anand Gautam ,  Søren Mouritsen

IPC分类号： A61K31/70 ,  A61K31/711 ,  C12N15/00 ,  C07H21/04

CPC分类号： C07K16/3069 ,  A61K39/0011 ,  C07K14/50 ,  C07K14/705 ,  C07K14/70539 ,  C07K14/71 ,  C07K2317/34 ,  C12N2799/021 ,  Y02A50/412

摘要： A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.

公开(公告)号：US07807441B2

公开(公告)日：2010-10-05

申请号：US11202516

申请日：2005-08-11

申请人： Lucilla Steinaa ,  Søren Mouritsen ,  Anand Gautam ,  Iben Dalum ,  Jesper Haaning ,  Dana Leach ,  Klaus Gregorius Nielsen ,  Gunilla Karlsson ,  Peter Birk Rasmussen

发明人： Lucilla Steinaa ,  Søren Mouritsen ,  Anand Gautam ,  Iben Dalum ,  Jesper Haaning ,  Dana Leach ,  Klaus Gregorius Nielsen ,  Gunilla Karlsson ,  Peter Birk Rasmussen

IPC分类号： C12N1/00 ,  C12N1/10 ,  C12N1/14 ,  C12N1/16 ,  C12N1/20 ,  C12N5/10 ,  C12N5/14 ,  C12N5/16 ,  C12N15/00 ,  A61K38/00 ,  C07K14/00

CPC分类号： C07K16/3069 ,  A61K39/0011 ,  C07K14/50 ,  C07K14/705 ,  C07K14/70539 ,  C07K14/71 ,  C07K2317/34 ,  C12N2799/021 ,  Y02A50/412

摘要： A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.

摘要翻译： 公开了一种用于诱导针对细胞抗原的细胞介导的免疫的方法。 更具体地，本发明提供了一种诱导针对弱抗原，特别是自身蛋白的细胞毒性T淋巴细胞免疫的方法。 该方法需要抗原呈递细胞被诱导以呈现弱抗原的至少一个CTL表位，并且同时呈现至少一种外来T辅助淋巴细胞表位。 在优选的实施方案中，抗原是癌特异性抗原，例如 PSM，Her2或FGF8b。 该方法可以通过使用传统的多肽疫苗接种，也可以通过使用活减毒疫苗或核酸接种来进行。 本发明还提供了PSM，Her2和FGF8b的免疫原性类似物以及编码这些类似物的核酸分子。 还公开了载体和转化的细胞。 本发明还提供了用于鉴定弱或非免疫原性抗原的免疫原性类似物的方法。